JAN 24, 2019 10:34 AM PST

Drug Blocks Toxic-Protein Production in ALS

WRITTEN BY: Nouran Amin

Individuals with ALS, frontotemporal dementia, carry a mutation in the gene C9orf72—resulting in repeated DNA sequences. These repetitions result in the production of toxic proteins that are associated with the development of ALS. Now, a new study aims to target a stress response with a known drug that may result in a decrease of toxic-protein production. "Both cellular stress and over-excitation eventually converge into the integrated stress response,” explains first author and graduate student, Thomas Westergard.

Learn more about ALS:

"Understanding what triggers toxic proteins production helped us hone in on drugs that could block them in laboratory tests," says co-senior author Aaron Haeusler, PhD, an Assistant Professor of Neuroscience within the Vickie & Jack Farber Institute for Neuroscience. Specifically, the researchers showed that the stress responses that trigger toxic protein production are similar to what happens during a seizure event.

The known drug used in the study is called ‘Trazodone’ and is currently approved for the treatment of depression and known to act on stress response. Trazodone was tested on models of the disease and was found to indeed inhibit toxic protein production of toxic protein in a cellular model contained the mutation. "This is a significant step forward in our collaborative approach," said co-author Dr. Piera Pasinelli, PhD, who lead the Jefferson Weinberg ALS Center. "Working together allowed us to speed up the research process getting from the identification of the "pathogenic stress" to testing a potentially useful drug. ALS is a complex and heterogenous disease that needs this collaborative approach, with each lab contributing its own expertise, to fill the gaps and to put together this complex puzzle in a systematic and efficient way.”

credit: healthiculture.com

Researchers are now looking forward to expand their studies for other compounds that might work better than trazodone. Results of the study were published in EMBO Molecular Medicine.

Source: Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 30, 2018
Drug Discovery
OCT 30, 2018
Re-sensitizing Drug-resistant Human Tumor Cells
Understanding how cancer cells avoid death despite their DNA being damaged will create new strategies to enhance cancer cell killing through chemotherapy t...
NOV 29, 2018
Cannabis Sciences
NOV 29, 2018
Want to Smoke Weed? For Science?
Clinical trials are a necessary part of the drug approval process. All drugs on the market, even the over-the-counter drugs, have gone through clinical tri...
DEC 04, 2018
Drug Discovery
DEC 04, 2018
Drug Combination May Be Effective for Melanoma
Protein kinase inhibitors have been noted to be the most effective class of drugs in the treatment of melanoma—a deadly skin cancer of the melanocyte...
DEC 27, 2018
Cannabis Sciences
DEC 27, 2018
Parents Turning to Medical Marijuana to Treat Children's Autism
WHEC News in Rochester, New York, is reporting that more adults are turning to medical marijuana to treat their child's autism. The parents claim that...
FEB 08, 2019
Drug Discovery
FEB 08, 2019
Apsirin Use Prevents Colorectal Cancer
In a study published in the American Journal of Medicine, the U.S. Preventive Services Task Force (USPSTF) concluded that aspirin use decreases the risk of...
FEB 17, 2019
Drug Discovery
FEB 17, 2019
Drug Improves Muscle Properties
Currently, adults over 65 are an increasingly growing segment in many countries. In the United States, the elderly population will increase by 40 percent w...
Loading Comments...